Major Depression Disorder (MDD) is accompanied by an immune response characterized by increased levels of pro-inflammatory and immune-regulatory cytokines and cytokine-induced stimulation of indoleamine-2,3-dioxygenase (IDO). There is also some evidence that antiinflammatory drugs may have a clinical efficacy in MDD.
on serum levels of IDO, interferon (IFN)-γ, interleukin (IL)-4 and transforming growth factor (TGF)-β1 in association with changes in the Beck-Depression Inventory-II (BDI-II). The study included 140 MDD patients and 40 normal controls.
The pre-treatment serum levels of IDO, IFN-γ, TGF-β1 and IL-4 were significantly higher in MDD patients compared with the control group. Treatment with sertraline with or without ketoprofen significantly reduced the increased baseline production of all 4 biomarkers to levels which were similar as those of normal controls. Ketoprofen add-on had a significantly greater effect on IDO and BDI-II as compared with placebo. The reductions in IDO, IL-4 and TGF-β1 during treatment were significantly associated with those in the BDI-II.
In conclusion, the clinical efficacy of both sertraline + ketoprofen may be ascribed at least in part to attenuated IDO levels and immune-inflammatory responses in MDD. Moreover, add-on treatment with ketoprofen may augment the efficacy of sertraline by attenuating IDO.
Introduction
There is now evidence that Major Depressive Disorder (MDD) is an immuneinflammatory disorder accompanied by higher levels of pro-inflammatory cytokines, acute phase proteins and complement factors (Maes, 1993; Al-Hakeim, 2008; Maes, 2011a; Köhler et al., 2017) . A recent review shows that MDD is accompanied by activation of M1 macrophages (with increased production of interleukin (IL)-1β and IL-6, T helper (Th)1 cells (with increased production of interferon (IFN)-γ), Th2 activation (with increased production of IL-4), and a T regulatory (Treg) response (with increased production of IL-10) (Maes and Carvalho, 2018) . This is important as IL-4 and IL-10 have immune regulatory effects attenuating the activation of Th1 and macrophagic M1 cells. This shows that MDD is accompanied by increased production and secretion of mediators that have immune regulatory or anti-inflammatory effects and that serve an adaptive purpose down-regulating the primary immune-inflammatory response. This new concept was called the "compensatory immune regulatory system" (CIRS) (Maes and Carvalho, 2018) .
Elevated production of IFN-γ and M1 macrophagic cytokines may lead to activation of peripheral and brain levels of indoleamine-2,3-dioxygenase (IDO) (Maes et al., 1994; 2011b) .
Cytokine-induced activation of this enzyme leads to increased degradation of L-tryptophan (TRP) resulting in decreased serotonin synthesis and concomitant increases in TRP catabolites (TRYCATs) (Maes et al., 1994; 2011b) . Therefore, activation of IDO may play a role in depression by taking TRP away from serotonin synthesis and increasing the production of neurotoxic and excitotoxic TRYCATS (Maes et al., 2002; Chaves Filho et al., 2011; Maes et al., 2011b) .
Studies indicate that in a considerable part of patients with MDD (30-40%), symptoms may be resistant to pharmacological treatment with antidepressants (Hernandez et al., 2013) .
Most antidepressant drugs are still designed to increase monoamine transmission either by inhibiting neuronal reuptake, e.g., by using TCAs, selective serotonin reuptake inhibitors (SSRIs), and serotonin noradrenaline reuptake inhibitors, or by inhibiting monoamine degradation, e.g., using monoamine oxidase inhibitors (David & Gardier 2016) . There is now also evidence that antidepressants have anti-inflammatory as well as immune-regulatory effects by attenuating the production of pro-inflammatory cytokines (IFN-γ and M1 macrophagic) and increasing that of negative immune-regulatory cytokines such as IL-10 and transforming growth factor (TGF)-β1, another Treg cytokine (Xia et al., 1996; Maes et al., 1999; Lee et al., 2006; Blatteau et al., 2015) . SSRIs including sertraline may change the proinflammatory / antiinflammatory cytokine balance via increasing production of IL-10 and TGF-β1, which have multiple suppressive actions on T cells, macrophages, and other cells (Maes et al., 1999; Lee et al. 2006) . Nevertheless, other studies showed that sertraline not only suppresses inflammatory cytokines, including IL-2, IL-6, IL-17 and IFN-γ, but also immune regulatory cytokines, including IL-4 and IL-10 (Brunoni et al., 2014) . Sertraline may also inhibit microglial activation through inhibition of IFN-γ-induced elevation of intracellular calcium ions (Horikawa et al., 2010) .
Depression is not only accompanied by increased levels of pro-inflammatory cytokines, but also by increased cyclooxygenase-2 (COX-2) expression and prostaglandin production (Song et al., 1998; Galecki et al., 2012; Maes et al., 2012a) . Consequently, COX-2 inhibitors are also of interest as adjunctive treatments in depression (Faridhosseini et al., 2014) . Similarly, agents with negative immune regulatory effects have potential antidepressant properties, including omega-3 polyunsatutrated fatty acids, infliximab, curcumin, aspirin, statins and N-acetylcysteine (Maes et al., 2012b; Fernandes et al., 2016) . Several clinical trials showed that adding non-steroidal antiinflammatory drugs (NSAIDs) such as COX inhibitors to SSRIs may help to reduce the severity of depression (Müller et al., 2013) . However, another large-scale study evaluating the efficacy of NSAIDs as mono-therapy for late-life depression in ~2500 elderly adults showed no significant effect in reducing depressive symptoms compared with placebo (Fields et al., 2012) . A recent meta-analysis pooling results from all available randomized trials testing NSAIDs and cytokine inhibitors as antidepressants showed that anti-inflammatory treatments reduced depressive symptoms compared with placebo (Köhler et al., 2014) . Nevertheless, there are no data whether treatments with sertraline with or without ketoprofen (a non-specific COX inhibitor that has antiinflammatory properties by inhibiting COX-2 thereby decreasing the production of proinflammatory prostaglandin precursors) significantly decreases IDO and the IFN-γ / IL-4 + TGF-β1 ratio in association with clinical recovery.
Hence, the aim of the present work was to study whether the efficacy of the antiinflammatory drug ketoprofen as an adjuvant therapy to traditional antidepressants (sertraline) is associated with reductions in IDO, IFN-γ levels and an increased IFN-γ / IL-4 + TGF-β1 ratio in MDD patients.
Materals and Methods

Participants
A total of one hundred and forty MDD patients and 40 normal controls participated in the present study. Patients were recruited at the Psychiatry Unit, Al-Hakeem General Hospital in Najaf Governorate-Iraq and at a private psychiatric clinic run by an assistant professor in psychiatric medicine during the period from November 2016-August 2017. The patients were diagnosed by psychiatrists according to a semi-structured psychiatric interview schedule for the diagnosis of MDD based on the ICD-10 (10 th revision of the International Statistical
Classification of Diseases and Related Health Problems). Forty apparently healthy subjects were selected as control group. Their sex and age were comparable to that of patients. These subjects were free from psychiatric (axis-1) and somatic diseases. Patients and controls were evaluated through a complete medical history to exclude any systemic diseases that may affect the biomarkers, including diabetes mellitus, liver and kidney diseases, (auto)immune disorders and neurological disorders, including multiple sclerosis, stroke and Parkinson's disorder. Exclusion criteria for participants were any systemic or inflammatory disease. C-reactive protein (CRP)
was not higher than 6 mg/L, excluding subjects with overt inflammation.
The present study is part of a prospective, 2-months, randomized double-blind study of parallel groups of patients with MDD with or without ketoprofen administration in addition to sertraline. In this study, we included 44 of the 140 MDD patients, namely those who had their blood sampled for biomarker assays at baseline and after the treatment. All biomarker assays were complete in these 44 subjects and there were no missing values in the BDI-II scores.
Among the follow up group, sixteen patients received traditional treatment (sertraline, orally 50 mg once daily) and twenty eight patients were treated with anti-inflammatory drug (ketoprofen, 100 mg orally once daily) as adjuvant to sertraline for treatment of MDD. Patients were instructed to take one capsule daily after breakfast. The coloured empty capsules (Caps & Chemicals, India) were filled either with sertraline (Actavis, Italy) alone, for the placebo group or filled with sertraline + ketoprofen (Menarini Int., Italy) for drug adjuvant group. The laboratory analysts were blinded to the treatment modalities. The protocol was approved by the IRB of the University of Kufa (#221, June 2016). The patients or their close first-degree relatives provided informed consent in accordance with the procedures outlined by the current IRB. The study is recorded in the NIH US Library of Medicine, ClinicalTrials.gov Identifier: NCT03514810.
Measurements
The total score on the Beck-Depression Inventory (BDI-II) (Beck et al., 1996) was used to rate severity of illness. The BDI-II score was obtained in all MDD patients at baseline and was also rated two months after starting treatment in the 44 patients who were included in the biomarker treatment study. Five milliliters of venous blood samples was drawn by utilizing disposable needles and plastic syringes. The samples were transferred into clean plain tubes.
Haemolyzed samples were discarded. The blood was left at room temperature for 10 minutes for clotting, centrifuged 3000 rpm for 5 minutes, and then serum was separated and transported into three new Eppindroff ® tubes until assay. Serum IDO, IL-4, INFγ, and TGF-β1 were measured by using ELISA kits supplied by MYBioSource ® Inc., USA. All kits were based on a sandwich technique and showed an inter-assay CV less than 12%. Briefly, serum containing analyte was added to the wells pre-coated with monoclonal antibody of the analyte. After incubation, a biotin-conjugated anti-human analyte antibody was added to bind the human analyte. After washing, streptavidin-HRP was added to bind to the biotin-conjugated anti-human analyte antibody and after incubation, the substrate solution was added followed by color development proportionally to the amount of human analyte. The reaction was terminated by addition of acidic stop solution and absorbance was measured at 450 nm and transformed into concentration by using standard curves.
Statistical Analysis
We used analysis of contingency tables (χ 2 test) to check associations between categorical variables and analysis of variance (ANOVAs) to check differences in continuous variables between groups. Protected pairwise post-hoc analyses were employed to examine the differences between group means. Multivariate general linear model (GLM) analysis was used to examine the effects of diagnosis (MDD versus controls) on the different biomarkers, which were entered as dependent variables. The primary outcome analysis is a linear mixed model (LMM) repeated measures analysis to assess responsivity of biomarkers to treatment with sertraline with or without ketoprofen from baseline to endpoint. The pre-specified LMM analyses included fixed categorical effects of ketoprofen treatment, time and time-by-treatment interactions; while sex and age were entered as random effects. Baseline data (demographic and clinical data) were assessed for balance between the ketoprofen and placebo treatment groups using analyses of contingency tables (χ 2 test) and ANOVAs. Power analysis to detect the add-on effects of ketoprofen on BDI-II scores, using a 2-tailed test at α=0.05 and assuming an effect size of 0.13 with power of 0.80, shows that the required sample size is around 142 participants. However, only 44 patients were included in the current biomarker study because the grant support was limited and, consequently, the present biomarker study shows a post-hoc achieved power of 0.658. Tests were 2-tailed and a p-value of 0.05 was used for statistical significance. All 
Results
Socio-demographic data Table 1 shows the socio-demographic, clinical and biomarker data of the participants in this study. In this table we examine differences in these variables between major depressed patients at baseline and healthy controls and between depressed patients at endpoint and controls.
The data were not adjusted for p-correction because the results of this Table (and the intercorrelation matrix between the variables) were used to determine the variables to be used as background (extraneous) variables in the ultimate multivariate analyses with the biomarkers as dependent variables. Nevertheless, this table shows that there were no significant differences in age, sex, employment status, rural/urban ratio, and BMI between the study groups. There were more smoking and not-married (single) subjects in the depressed group as compared with controls. The levels of IDO, IFN-γ, IL-4, TGF-β and the index Th2 + Treg were significantly different between major depressed patients at baseline and normal controls. There were no significant differences in the Th1 / Th2+Treg ratio between major depressed patients at baseline and healthy controls. There were no significant differences in levels of IDO, IFN-γ, IL-4, TGF-β and the Th2 + Treg and Th1 / Th2 + Treg indices between MDD post-treatment and control values.
After p-correction there were significant associations between IDO and levels of p=0.028 ) and the Th2 + Treg index (r=0.222, p=0.015), but not IFN-γ (r=0.130, p=0.103) or the Th1 / Th2 + Treg index (r=-0.012, p=0.873) (all n=180, performed on all controls and depressed patients at baseline). After p-correction, we found that IFN-γ was significantly associated with IL-4 (r=0.455, p<0.001), TGF-β1 (r=309, p<0.001) and Th2 + Treg index (r=0.488, p<0.001) (all n=180). There were also significant association between IL-4 and TGF-β1 (r=0.282, p<0.01). In patients there were no significant associations between the baseline immune biomarkers and pre-treatment BDI-II scores.
Differences in the biomarkers between major depressed patients at baseline and controls Table 2 shows the outcome of a multivariate GLM analysis with the 6 biomarker values as dependent variables and diagnosis as primary outcome variable, while adjusting for sex, TUD, age and BMI. We found a highly significant association between the biomarkers (at baseline) and diagnosis. Tests for between-subjects effects showed that IDO, the three cytokines / chemokines and the Th2 + Treg score, but not the Th1 /Th2 + Treg score, were significantly associated with diagnosis with a particularly strong effect on IL-4 (partial η 2 =0.203), the Th2 + Treg index (partial η 2 =0.185) and IFN-γ (partial η 2 =0.122). There were no significant associations between diagnosis and the Th1 / Th2 + Treg score. values of the 6 biomarkers obtained by the GLM analysis shown in Table 2 . The levels of IDO, IFN-γ, IL-4, TGF-β and the Th2 + Treg index were all significantly greater in MDD than in healthy controls.
Effects of treatments on the BDI-II score and immune biomarkers. Table 4 shows the baseline characteristics of both treatment groups. We found no significant differences in any of the demographic (age, sex, marital and employment status, urban/rural ratio) and clinical (baseline BDI, BMI and TUD) data between both treatment groups. In addition, there were no significant differences in any of the baseline biomarker levels between both treatment groups. There were also no significant differences in age, sex ratio, smokers, BDI-II score, IDO, IFN-γ, IL-10 and TGF-β1 between the 44 MDD patients who had biomarker assays after treatment and the remaining 96 MDD patients. Using LMM analysis we also examined the associations between changes in the BDI-II and biomarker levels. LMM analysis (adjusted for treatment and all extraneous variables shown in 
Discussion
1-Comparison of the baseline biomarkers between MDD patients and controls
The first major finding of this study is that IDO and the three cytokines measured here were significantly higher in MDD patients than in normal controls. A significant increase in IDO levels in MDD patients was previously reported in some papers (Zoga et al., 2014; Kopschina Feltes et al., 2017) . Not all authors, however, could find increased IDO activity as estimated by Finally, while the current study reports increased TGF-β1 levels in MDD, a previous meta-analysis did not find any changes in this cytokine (Köhler et al., 2017) . 
3-Effects of antidepressive treatments on the biomarkers.
The second major finding of this study is that antidepressants significantly reduced IDO, IFN-γ, TGF-β1 and IL-4 concentrations to levels which were in the range of the values observed in our normal controls. According to Beck's criteria (Beck 1996) , most patients in our study showed at baseline a severe depression (score between 29 and 63), while after treatment the BDI-II scores were significantly reduced to values reflecting minimal depression (46.15%), mild depression (30.77%) and moderate depression (23.08%). There is now evidence that antidepressant treatments reduce the BDI-II score, which is therefore an adequate outcome measurement in clinical trials (Kolouri et al., 2016; Zamanian et al., 2017) . Already in the 1990ties it was shown that antidepressants have in vitro immune regulatory effects by lowering the production of pro-inflammatory M1 and Th1 cytokines (Xia et al., 1996; Maes et al., 1999) . A 12-week treatment with antidepressants decreased IFN-γ levels to concentrations measured in healthy subjects (Dahl et al., 2014) . In contrast to our findings, Lee et al. (2006) found that plasma TGF-β1 levels were significantly increased after 8-week Secondly, the reductions in IL-4 following our treatments may attenuate the above-mentioned more detrimental effects of IL-4, but is of course also accompanied by lowered immune regulation. Moreover, TGF-β1 has strong negative regulatory effects (Maes and Carvalho, 2018) although it also has some pro-inflammatory effects including effects on Th17 and Th1 cytokines (Han et al., 2012) . Therefore, it remains unknown whether the significant correlations between clinical and immune responses as found in the current study indicate causal associations, and if so, which molecules may explain this association (IDO, IFN-γ, IL-4 and TGF-β1, alone or together). The most parsimonious explanation at this stage is that during antidepressant treatment the primary immune response is suppressed and that this is accompanied by a clinical improvent.
4-Add-on effects of ketoprofen
The third major finding of this study is that ketoprofen was significantly more efficacious in reducing IDO and the BDI-II score than placebo, although ketoprofen had no additional effects suppressing cytokine levels. Nevertheless, the significant effect of ketoprofen on IDO 
Limitation of the study
It would have been more interesting if we had included different M1 macrophagic cytokines, Th1 cytokines including IL-12 and IL-2, Th2 cytokines including IL-5 and especially the Treg cytokine IL-10. This would allow us to compute more comprehensive immune activation / CIRS ratios. Moreover, the size of the study sample did not achieve adequate power (0.658) to detect effects of add-on treatment with ketoprofen, although the effects of treatment on the measurements were well powered in a post-hoc power analysis (around 0.95).
Conclusions
The acute phase of depression is characterized by an interrelated response in Th1, Th2
and Treg phenotypes and increased IDO levels, while antidepressant treatment with sertraline normalized all these different phenotypes as well as IDO in association with clinical improvement. Treatment with sertraline with or without ketoprofen significantly reduced the BDI-II score, while ketoprofen add-on had a significantly greater effect on the BDI-II score than placebo. The clinical efficacy of sertraline and sertraline + ketoprofen may be ascribed to a reduction of the immune response in MDD. However, this treatment may also significantly reduce the more beneficial properties of Th2 and Treg immune subsets.
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